In this Healthed lecture, Dr Robert Hungerford discusses the latest evidence-based recommendation to lower LDL-C targets even further in various at-risk groups, as well as the most effective means of reaching those targets in real-world Australian clinical practice. He will also present the value of combination therapy, the value of starting combination early, the role of the newer PCSK9 inhibitors and their current PBS eligibility criteria.

H5N1 avian influenza: Global threats, local preparedness and key risk groups
27:09

Long COVID Part 2 – Treatment
41:27

COVID surge update, booster news, new vaccine and more
29:32